글로벌 연구동향
방사선종양학
- 2022년 03월호
[Anticancer Res.] Enhancement of Radiation Response Associated With Metformin in Hepatocellular Carcinoma: Preclinical Animal and Clinical Cohort StudyKIRAMS / 장원일, 김미숙*, 김원우*
- 출처
- Anticancer Res.
- 등재일
- 2022 Feb
- 저널이슈번호
- 42(2):867-876. doi: 10.21873/anticanres.15544.
- 내용
Abstract
Background/aim: This study examined whether metformin can enhance the radiation response in a hepatocellular carcinoma (HCC) xenograft mice model and patient population.Materials and methods: Huh-7 human HCC-bearing xenograft mice were treated with gamma-ray, metformin, neutron therapy, and their combinations. Tumour growth and lung colonies were assessed. Overall, 145 patients who underwent radiotherapy for HCC were retrospectively analysed.
Results: The combinations of gamma-ray and metformin and neutron radiation and metformin inhibited tumour growth and metastatic lung nodule formation when compared to the monotherapy and gamma-ray groups, respectively. In patients who received radiotherapy for HCC, the overall survival rate was higher in the metformin-treated group than in the non-metformin group.
Conclusion: Metformin inhibited tumour growth and metastasis in HCC by enhancing the radiation response in animal experiments. Additionally, metformin was also found to be associated with a higher survival outcome in patients with HCC.
Affiliations
Won Il Jang 1 2 , Mi-Sook Kim 3 , Jae-Hoon Jeong 4 , Wonwoo Kim 5 , Jae Sung Kim 2 6
1 Department of Radiation Oncology, Korea Institute of Radiological and Medical Sciences, Seoul, Republic of Korea.
2 Department of Radiation Oncology, Seoul National University College of Medicine, Seoul, Republic of Korea.
3 Department of Radiation Oncology, Korea Institute of Radiological and Medical Sciences, Seoul, Republic of Korea; mskim@kirams.re.kr wwkim@enzychem.com.
4 Applied Cancer Research Team, Korea Institute of Radiological and Medical Sciences, Seoul, Republic of Korea.
5 R&D Center, Enzychem Lifesciences, Seoul, Republic of Korea; mskim@kirams.re.kr wwkim@enzychem.com.
6 Department of Radiation Oncology, Seoul National University Bundang Hospital, Seongnam, Republic of Korea.
- 키워드
- Hepatocellular carcinoma; metformin; neutron; radiosensitizer; radiotherapy; xenograft.
- 연구소개
- 당뇨약으로 사용되고 있는 metformin 은 전임상 실험을 통하여 암세포의 사멸 및 면역 반응등 metabolic reaction 뿐만 아닌 mulitple molecular reaction을 통해 anticancer 의 역할을 하는 것으로 알려져 있다. 이 논문은 마우스의 간암 모델 및 간암으로 방사선 치료를 받은 환자를 대상으로 한 후향적 연구를 통하여 metformin 이 방사선치료의 효과를 증진 시킬 수 있다는 것을 보여주었다. 아직은 동물에 사용되고 있는 high-dose 의 metformin을 암환자에 실제 사용 할 수는 없지만 metformin의 아직 정확히 밝혀지지 않은 mechanism을 향후 규명함으로써 좀 더 낮은 dose 의 metformin을 사용하여 방사선치료의 효과를 증진 시킬 수 있는 임상 연구가 필요할 것으로 생각합니다.
- 덧글달기
- 이전글 [Int J Clin Oncol.] Comparison of treatment outcomes of pelvis external radiotherapy with and without vaginal brachytherapy for cervical cancer patients with positive or close vaginal resected margins
- 다음글 [Sci Rep.] Clinical significance of quantitative bone SPECT/CT in the evaluation of hand and wrist pain in patients with rheumatic disease